PhAST Clinic: Point-of-Need AI Diagnostic Platform

PhAST has developed a phenotypic AST approach with TTR <100 min directly from urine specimens

The PhAST Clinic hardware is relatively simple, and thus affordable, while still delivering strong performance that meets or exceeds FDA requirements.

  • Infection prevention
  • Antimicrobial stewardship
  • Microbial diagnostics

  • Bacteria

  • Human

Development stage:
  • Development
  • Validation

  • Company

  • License, Co-develop, Outsource, Joint Venture, Sell

Infectious disease area:
  • UTI
  • BSI

Geographic origin:
  • North America

PhAST is an AI diagnostics company developing a computer-vision platform for the rapid detection of pathogens and associated phenotypic-based AST.

The initial exemplar assay is UTIs. Preliminary work has shown that the same approach works on positive blood cultures in 100 min, faster than any other available phenotypic AST approach. Other potential assays include STIs, fungi, and yeast.

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!